Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Contact
About us
Links
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Contact
About us
Links
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
About us
Contact
Links
About us
Contact
Links
Accordion Title
Accordion Content
more items +
Here’s why AMD’s stock is rising — and sending a confident message about the AI trade
AI’s control over the bond market is growing — even rivaling war and elections
S&P 500 is looking over the edge of a technical cliff — what happens if it falls off?
Depressing, but true: If you want to get ahead at work, embrace virtue signaling
Super Micro’s stock pops as earnings show booming demand for AI servers
Anthropic’s IPO is a high-stakes referendum on Big Tech — and this chart proves it
The internet is ‘dying’: AI is eating it and obliterating these business models
An overlooked energy source could solve AI’s power crunch — and these 2 stocks are prime plays
Medicare prescription drug costs will jump 50% in 2027. Doing nothing could cost you.
Once election results are in, here’s what investors should focus on next
U.S. jobs market perks up, but it’s still not a great time to get hired
U.S. clears path for first regulated equity perpetual futures
Here’s why AMD’s stock is rising — and sending a confident message about the AI trade
AI’s control over the bond market is growing — even rivaling war and elections
S&P 500 is looking over the edge of a technical cliff — what happens if it falls off?
Depressing, but true: If you want to get ahead at work, embrace virtue signaling
Super Micro’s stock pops as earnings show booming demand for AI servers
Anthropic’s IPO is a high-stakes referendum on Big Tech — and this chart proves it
The internet is ‘dying’: AI is eating it and obliterating these business models
An overlooked energy source could solve AI’s power crunch — and these 2 stocks are prime plays
Medicare prescription drug costs will jump 50% in 2027. Doing nothing could cost you.
Once election results are in, here’s what investors should focus on next
U.S. jobs market perks up, but it’s still not a great time to get hired
U.S. clears path for first regulated equity perpetual futures
Nasdaq-100 tumbles into its third correction this year as AI worries mount
3-11-26
The “tech wreck” from October continues. Is a bear market next?
Share this on:
